Skip to main content
main-content

01.12.2017 | Review | Ausgabe 1/2017 Open Access

Clinical and Translational Allergy 1/2017

Looking forward to new targeted treatments for chronic spontaneous urticaria

Zeitschrift:
Clinical and Translational Allergy > Ausgabe 1/2017
Autoren:
Emek Kocatürk, Marcus Maurer, Martin Metz, Clive Grattan
Wichtige Hinweise
An erratum to this article is available at http://​dx.​doi.​org/​10.​1186/​s13601-017-0148-9.

Abstract

The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU. Off-licence uses of currently available drugs include rituximab and tumour necrosis factor inhibitors. Ligelizumab (anti-IgE), canakinumab (anti-IL-1), AZD1981 (a PGD2 receptor antagonist) and GSK 2646264 (a selective Syk inhibitor) are currently in clinical trials for CSU. Examples of drugs that could target potential pathophysiological targets in CSU include substance P antagonists, designed ankyrin repeat proteins, C5a/C5a receptor inhibitors, anti-IL-4, anti-IL-5 and anti-IL-13 and drugs that target inhibitory mast cell receptors. Other mediators and receptors of likely pathogenic relevance should be explored in skin profiling and functional proof of concept studies. The exploration of novel therapeutic targets for their role and relevance in CSU should help to achieve a better understanding of its etiopathogenesis.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Clinical and Translational Allergy 1/2017 Zur Ausgabe